BioXell to regain TREM rights from Merck & Co
Italian biopharmaceutical company BioXell SpA says that it will regain full rights to its TREM platform from development partner, US drug major Merck & Co, originally licensed under a collaboration accord established in 2005 (Marketletters passim). The firm said that the transfer was a result of Merck's decision to streamline its R&D operations in the area of inflammatory diseases.
Enrico Colli, BioXell's chief medical officer, said that the collaboration had allowed the firm to make significant advances in the creation of a TREM-based sepsis treatment. He added that the firm intends to seek another major pharmaceutical partner with which it can continue the drug's development.
Initiates Ph II elocalcitol trial
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze